Odds for remission in T2 severe asthma greater with dupilumab vs. other biologics

The odds for clinical remission achievement in patients with type 2 inflammatory severe asthma were greater with dupilumab vs. other biologics, according to a poster presented at the European Respiratory Society International Congress.“While dupilumab is already approved for eligible patients with asthma, including those with higher levels of type 2 inflammatory biomarkers, these results